Artiva Biotherapeutics, Inc.

ARTV Healthcare Biotechnology

Artiva Biotherapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $251,000.00, down 99.3% from fiscal 2023. In the quarter to June 2026, EPS grew 27.6% and free cash flow grew 13.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

5.85 0.21 −3.47%
Market cap
$296.3M
P/E
0.0×
Fwd P/E
−1.4×
Dividend yield
—
F-score
n/a
Altman Z
1.27
Beneish M
−22.63
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
— — — —

+8 more quarters

EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
24.16 8.16 8.61 11.65
Net Debt/EBITDA
13.34 3.65 5.08 5.53
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(0.53) (0.86) (0.62) (0.81)
Book value per Share
8.82 3.56 4.50 5.28
Free Cash Flow
(20.77) (21.19) (15.15) (19.80)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates